Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract

Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis

See more here